Thioridazine for treatment of tuberculosis: Promises and pitfalls

Tuberculosis

Volumn 94, Issue 6, 2014, Pages 708-711

  Dutta, Noton K ^a   Karakousis, Petros C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adjunctive therapy; Animal model; Efflux pump inhibitor; Latent TB; Mycobacterium tuberculosis; Thioridazine

Indexed keywords

THIORIDAZINE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

BACTERICIDAL ACTIVITY; DELAYED HYPERSENSITIVITY; DRUG RESISTANT TUBERCULOSIS; HUMAN; MUTATION RATE; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; RECURRENCE RISK; REVIEW; ANIMAL; DRUG EFFECTS; FEMALE; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; FEMALE; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; THIORIDAZINE; TUBERCULOSIS;

EID: 84919499390     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2014.09.001     Document Type: Note

References (78)

1. A.M. Ginsberg Tuberculosis drug development: progress, challenges, and the road ahead Tuberculosis (Edinb) 90 2010 162 167
2. N.K. Dutta, and P.C. Karakousis Tuberculosis chemotherapy: present situation, possible solutions, and progress towards a TB-free world Indian J Med Microbiol 30 2012 261 263
3. Z. Ma, C. Lienhardt, H. McIlleron, A.J. Nunn, and X. Wang Global tuberculosis drug development pipeline: the need and the reality Lancet 375 2010 2100 2109
4. E.L. Nuermberger, M.K. Spigelman, and W.W. Yew Current development and future prospects in chemotherapy of tuberculosis Respirology 15 2010 764 778
5. J. van den Boogaard, G.S. Kibiki, E.R. Kisanga, M.J. Boeree, and R.E. Aarnoutse New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development Antimicrobial Agents Chemother 53 2009 849 862
6. K. Mdluli, T. Kaneko, and A. Upton Tuberculosis drug discovery and emerging targets Ann N Y Acad Sci 1323 1 2014 Sep 56 75 10.1111/nyas.12459
7. S.H. Gillespie Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective Antimicrobial Agents Chemother 46 2002 267 274
8. J.C. Palomino, and A. Martin Is repositioning of drugs a viable alternative in the treatment of tuberculosis? J Antimicrob Chemother 68 2013 275 283
9. Thioridazine Tuberculosis (Edinb) 88 2008 164 167
10. M.J. Boeree Global clinical trials for the treatment of TB with thioridazine Recent Pat Antiinfect Drug Discov 6 2011 99 103
11. L. Amaral, M.J. Boeree, S.H. Gillespie, Z.F. Udwadia, and D. van Soolingen Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents 35 2010 524 526
12. L. Amaral, Z. Udwadia, E. Abbate, and D. van Soolingen The added effect of thioridazine in the treatment of drug-resistant tuberculosis Int J Tuberc Lung Dis 16 2012 1706 1708 Author reply 8-9
13. R.H. Thanacoody Thioridazine: the good and the bad Recent Pat Antiinfect Drug Discov 6 2011 92 98
14. L. Amaral, J.E. Kristiansen, L.S. Abebe, and W. Millett Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis J Antimicrob Chemother 38 1996 1049 1053
15. L. Amaral, J.E. Kristiansen, M. Viveiros, and J. Atouguia Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy J Antimicrob Chemother 47 2001 505 511
16. L. Amaral, M. Viveiros, and J.E. Kristiansen "Non-Antibiotics": alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries Curr Drug Targets 7 2006 887 891
17. M.V. Bettencourt, S. Bosne-David, and L. Amaral Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis Int J Antimicrob Agents 16 2000 69 71
18. D. Ordway, M. Viveiros, C. Leandro, R. Bettencourt, J. Almeida, and M. Martins Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis Antimicrobial Agents Chemother 47 2003 917 922
19. M. Martins, Z. Schelz, A. Martins, J. Molnar, G. Hajos, and Z. Riedl In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis Int J Antimicrob Agents 29 2007 338 340
20. F.G. Winder, and P.B. Collins Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis J Gen Microbiol 63 1970 41 48
21. K. Takayama, L. Wang, and H.L. David Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis Antimicrobial Agents Chemother 2 1972 29 35
22. Z. Xie, N. Siddiqi, and E.J. Rubin Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates Antimicrobial Agents Chemother 49 2005 4778 4780
23. C.D. Sohaskey Nitrate enhances the survival of Mycobacterium tuberculosis during inhibition of respiration J Bacteriol 190 2008 2981 2986
24. C. Sohaskey Latent tuberculosis: is there a role for thioridazine? Recent Pat Antiinfect Drug Discov 6 2011 139 146
25. S. Salie, N.J. Hsu, D. Semenya, A. Jardine, and M. Jacobs Novel non-neuroleptic phenothiazines inhibit Mycobacterium tuberculosis replication J Antimicrob Chemother 69 2014 1551 1558
26. S. Musuka, S. Srivastava, C.W. Siyambalapitiyage Dona, C. Meek, R. Leff, and J. Pasipanodya Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners Antimicrobial Agents Chemother 57 2013 5870 5877
27. G.J. de Knegt Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy 2014
28. N.K. Dutta, M.L. Pinn, and P.C. Karakousis Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis Antimicrobial Agents Chemother 58 2014 4048 4053
29. M. Viveiros, and L. Amaral Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines Int J Antimicrob Agents 17 2001 225 228
30. N.K. Dutta, S. Mehra, and D.A. Kaushal Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine PLoS One 5 2010 e10069
31. N.K. Dutta, K. Mazumdar, S.G. Dastidar, P.C. Karakousis, and L. Amaral New patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: a gene regulation perspective Recent Pat Antiinfect Drug Discov 6 2011 128 138
32. S.P. Rao, S. Alonso, L. Rand, T. Dick, and K. Pethe The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis Proc Natl Acad Sci U S A 105 2008 11945 11950
33. H.I. Boshoff, T.G. Myers, B.R. Copp, M.R. McNeil, M.A. Wilson, and C.E. Barry III The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action J Biol Chem 279 2004 40174 40184
34. T. Yano, L.S. Li, E. Weinstein, J.S. Teh, and H. Rubin Steady-state kinetics and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2) J Biol Chem 281 2006 11456 11463
35. S. Mehra, N.K. Dutta, H.J. Mollenkopf, and D. Kaushal Mycobacterium tuberculosis MT2816 encodes a key stress-response regulator J Infect Dis 202 2010 943 953
36. N.K. Dutta, S. Mehra, P.J. Didier, C.J. Roy, L.A. Doyle, and X. Alvarez Genetic requirements for the survival of tubercle bacilli in primates J Infect Dis 201 2010 1743 1752
37. N.K. Dutta, N. Bandyopadhyay, B. Veeramani, G. Lamichhane, P.C. Karakousis, and J.S. Bader Systems biology-based identification of Mycobacterium tuberculosis persistence genes in mouse lungs MBio 5 2014
38. K.N. Adams, K. Takaki, L.E. Connolly, H. Wiedenhoft, K. Winglee, and O. Humbert Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism Cell 145 2011 39 53
39. V. Dartois The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells Nat Rev Microbiol 12 2014 159 167
40. L. Rodrigues, D. Wagner, M. Viveiros, D. Sampaio, I. Couto, and M. Vavra Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis J Antimicrob Chemother 61 2008 1076 1082
41. D. Machado, I. Couto, J. Perdigao, L. Rodrigues, I. Portugal, and P. Baptista Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis PLoS One 7 2012 e34538
42. L. Amaral, M. Martins, and M. Viveiros Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps J Antimicrob Chemother 59 2007 1237 1246
43. N.K. Dutta, M.L. Pinn, M. Zhao, M.A. Rudek, and P.C. Karakousis Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis J Antimicrob Chemother 68 2013 1327 1330
44. M. Martins, M. Viveiros, J.E. Kristiansen, J. Molnar, and L. Amaral The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis In Vivo 21 2007 771 775
45. D. van Soolingen, R. Hernandez-Pando, H. Orozco, D. Aguilar, C. Magis-Escurra, and L. Amaral The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis PLoS One 5 2010
46. N.K. Dutta, M.L. Pinn, and P.C. Karakousis Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine TB Antimicrobial Agents Chemother 58 9 2014 5567 5569 10.1128/AAC.03408-14
47. P.A. Black, R.M. Warren, G.E. Louw, P.D. van Helden, T.C. Victor, and B.D. Kana Energy metabolism and drug efflux in Mycobacterium tuberculosis Antimicrobial Agents Chemother 58 2014 2491 2503
48. E. Abbate, M. Vescovo, M. Natiello, M. Cufre, A. Garcia, and P. Gonzalez Montaner Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine J Antimicrob Chemother 67 2012 473 477
49. Z.F. Udwadia, T. Sen, and L.M. Pinto Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB Recent Pat Antiinfect Drug Discov 6 2011 88 91
50. C.K. Kwan, and J.D. Ernst HIV and tuberculosis: a deadly human syndemic Clin Microbiol Rev 24 2011 351 376
51. A. Pawlowski, M. Jansson, M. Skold, M.E. Rottenberg, and G. Kallenius Tuberculosis and HIV co-infection PLoS Pathog 8 2012 e1002464
52. N.K. Dutta, and P.C. Karakousis Latent tuberculosis infection:myths, models, and molecular mechanisms Microbiol Mol Biol Rev 78 2014
53. C.R. Horsburgh Jr., and E.J. Rubin Clinical practice. Latent tuberculosis infection in the United States N Engl J Med 364 2011 1441 1448
54. E. Nuermberger, W.R. Bishai, and J.H. Grosset Latent tuberculosis infection Semin Respir Crit Care Med 25 2004 317 336
55. E.L. Opie, and J.D. Aronson Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions Arch Pathol Lab Med 4 1927 1 21
56. J.H. Haapanen, I. Kass, G. Gensini, and G. Middlebrook Studies on the gaseous content of tuberculous cavities Am Rev Respir Dis 80 1959 1 5
57. J.E. Gomez, and J.D. McKinney Persistence and drug tolerance W.N. Rom, S.M. Garay, Tuberculosis 2nd ed. 2004 Lippincott Williams & Wilkins Philadelphia 101 114
58. W. McDermott Inapparent infection: relation of latent and dormant infections to microbial persistence Public Health Rep 74 1959 485 499
59. R.M. Jasmer, P. Nahid, and P.C. Hopewell Clinical practice. Latent tuberculosis infection N Engl J Med 347 2002 1860 1866
60. T.P. Primm, S.J. Andersen, V. Mizrahi, D. Avarbock, H. Rubin, and C.E. Barry III The stringent response of Mycobacterium tuberculosis is required for long-term survival J Bacteriol 182 2000 4889 4898
61. J.L. Dahl, C.N. Kraus, H.I. Boshoff, B. Doan, K. Foley, and D. Avarbock The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice Proc Natl Acad Sci U S A 100 2003 10026 10031
62. H. Bloch, and W. Segal Biochemical differentiation of Mycobacterium tuberculosis grown in vivo and in vitro J Bacteriol 72 1956 132 141
63. Y.C. Manabe, and W.R. Bishai Latent Mycobacterium tuberculosis-persistence, patience, and winning by waiting Nat Med 6 2000 1327 1329
64. T. Zhang, M. Zhang, I.M. Rosenthal, J.H. Grosset, and E.L. Nuermberger Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection Am J Respir Crit Care Med 180 2009 1151 1157
65. T. Zhang, S.Y. Li, K.N. Williams, K. Andries, and E.L. Nuermberger Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection Am J Respir Crit Care Med 184 2011 732 737
66. Amandeep Singh, and Sadhna Sharma Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis 2014 10.1016/j.tube.2014.08.016
67. J. Flynn, and J. Chan Animal models of tuberculosis W. Rom, S. Garay, Tuberculosis 2nd ed. 2004 Lippincott Williams & Wilkins Philadelphia 237 250
68. D.N. McMurray Disease model: pulmonary tuberculosis Trends Mol Med 7 2001 135 137
69. S. Subbian, P. O'Brien, N.L. Kushner, G. Yang, L. Tsenova, and B. Peixoto Molecular immunologic correlates of spontaneous latency in a rabbit model of pulmonary tuberculosis Cell Commun Signal 11 2013 16
70. J.L. Flynn, S.V. Capuano, D. Croix, S. Pawar, A. Myers, and A. Zinovik Non-human primates: a model for tuberculosis research Tuberculosis (Edinb) 83 2003 116 118
71. H. Pan, B.S. Yan, M. Rojas, Y.V. Shebzukhov, H. Zhou, and L. Kobzik Ipr1 gene mediates innate immunity to tuberculosis Nature 434 2005 767 772
72. J. Harper, C. Skerry, S.L. Davis, R. Tasneen, M. Weir, and I. Kramnik Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions J Infect Dis 205 2012 595 602
73. L.E. Via, P.L. Lin, S.M. Ray, J. Carrillo, S.S. Allen, and S.Y. Eum Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates Infect Immun 76 2008 2333 2340
74. J.P. Lanoix, F. Betoudji, and E. Nuermberger Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis Antimicrobial Agents Chemother 58 2014 2316 2321
75. S.M. Irwin, V. Gruppo, E. Brooks, J. Gilliland, M. Scherman, and M.J. Reichlen Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas Antimicrobial Agents Chemother 58 2014 4026 4034
76. C. Vilaplana, E. Marzo, G. Tapia, J. Diaz, V. Garcia, and P.J. Cardona Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis J Infect Dis 208 2013 199 202
77. N.K. Dutta, P.B. Illei, S.K. Jain, and P.C. Karakousis Characterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice Am J Pathol 184 2014 2045 2055
78. K.C. Chang, W.W. Yew, C.M. Tam, and C.C. Leung WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis Antimicrobial Agents Chemother 57 2013 4097 4104